Clinicopathological correlation of ARID1A status with HDAC6 and its related factors in ovarian clear cell carcinoma
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Clinicopathological correlation of ARID1A status with HDAC6 and its related factors in ovarian clear cell carcinoma
Authors
Keywords
-
Journal
Scientific Reports
Volume 9, Issue 1, Pages -
Publisher
Springer Nature
Online
2019-02-20
DOI
10.1038/s41598-019-38653-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Blockade of histone deacetylase 6 protects against cisplatin-induced acute kidney injury
- (2018) Jinhua Tang et al. CLINICAL SCIENCE
- A novel HDAC6 inhibitor exerts an anti-cancer effect by triggering cell cycle arrest and apoptosis in gastric cancer
- (2018) Jing Dong et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors
- (2018) Jooeun Bae et al. LEUKEMIA
- ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade
- (2018) Jianfeng Shen et al. NATURE MEDICINE
- Repurposing Pan-HDAC Inhibitors for ARID1A -Mutated Ovarian Cancer
- (2018) Takeshi Fukumoto et al. Cell Reports
- Combination of a novel HDAC6 inhibitor ACY-241 and anti-PD-L1 antibody enhances anti-tumor immunity and cytotoxicity in multiple myeloma
- (2017) A Ray et al. LEUKEMIA
- ARID1A-mutated ovarian cancers depend on HDAC6 activity
- (2017) Benjamin G. Bitler et al. NATURE CELL BIOLOGY
- HDAC6 inhibition effectively reverses chemotherapy-induced peripheral neuropathy
- (2017) Karen Krukowski et al. PAIN
- HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer
- (2017) Teru Hideshima et al. Oncotarget
- Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial
- (2016) Andrew J Yee et al. LANCET ONCOLOGY
- Essential role of HDAC6 in the regulation of PD-L1 in melanoma
- (2016) M. Lienlaf et al. Molecular Oncology
- Structural insights into HDAC6 tubulin deacetylation and its selective inhibition
- (2016) Yasuyuki Miyake et al. Nature Chemical Biology
- ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A
- (2016) Chris T. Williamson et al. Nature Communications
- Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor ACY-1215 and Bortezomib Is Synergistic in Lymphoma
- (2015) J. E. Amengual et al. CLINICAL CANCER RESEARCH
- HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade
- (2015) D. M. Woods et al. Cancer Immunology Research
- Discovery and saturation analysis of cancer genes across 21 tumour types
- (2014) Michael S. Lawrence et al. NATURE
- Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
- (2014) Katrina J. Falkenberg et al. NATURE REVIEWS DRUG DISCOVERY
- Alterations of Hypoxia-Induced Factor Signaling Pathway Due to Mammalian Target of Rapamycin (mTOR) Suppression in Ovarian Clear Cell Adenocarcinoma
- (2013) Takeshi Hirasawa et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy
- (2013) Cigall Kadoch et al. NATURE GENETICS
- Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma
- (2012) L. Santo et al. BLOOD
- Depletion of HDAC6 Enhances Cisplatin-Induced DNA Damage and Apoptosis in Non-Small Cell Lung Cancer Cells
- (2012) Lei Wang et al. PLoS One
- Mutation and Loss of Expression of ARID1A in Uterine Low-grade Endometrioid Carcinoma
- (2011) Bin Guan et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Suberoylanilide hydroxamic acid partly reverses resistance to paclitaxel in human ovarian cancer cell lines
- (2010) Adriano Angelucci et al. GYNECOLOGIC ONCOLOGY
- Prognostic Relevance of Uncommon Ovarian Histology in Women With Stage III/IV Epithelial Ovarian Cancer
- (2010) Helen J. Mackay et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Differences in Tumor Type in Low-stage Versus High-stage Ovarian Carcinomas
- (2010) Martin Köbel et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY
- Increasing CD44+/CD24- tumor stem cells, and upregulation of COX-2 and HDAC6, as major functions of HER2 in breast tumorigenesis
- (2010) Kai-Hung Wang et al. Molecular Cancer
- ARID1AMutations in Endometriosis-Associated Ovarian Carcinomas
- (2010) Kimberly C. Wiegand et al. NEW ENGLAND JOURNAL OF MEDICINE
- Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma
- (2010) Siân Jones et al. SCIENCE
- Association of Estrogen Receptor and Histone Deacetylase 6 Causes Rapid Deacetylation of Tubulin in Breast Cancer Cells
- (2009) K. Azuma et al. CANCER RESEARCH
- A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study
- (2008) Susan C. Modesitt et al. GYNECOLOGIC ONCOLOGY
- Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers
- (2008) John K. Chan et al. GYNECOLOGIC ONCOLOGY
- Therapeutic strategy targeting the mTOR-HIF-1α-VEGF pathway in ovarian clear cell adenocarcinoma
- (2008) Masaki Miyazawa et al. PATHOLOGY INTERNATIONAL
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now